ARLEVERT . 48 tablets
ARLEVERT . 48 tablets
1 tablet contains 20 mg Cinnarizine and Dimenhydrinate 40 mg in combination;
Talc, magnesium stearate, microcrystalline cellulose, corn starch, cellulose ether 2-hidroksipropilmetil, colloidal silica, sodium croscarmellose.
Treatment of vertigo of various origins
Special warnings and precautions for use:
Arlevert not significantly lowered blood pressure, but should be used with caution in patients with low blood pressure. It can cause epigastric discomfort, but taking it after a meal reduces stomach irritation.
Precautions for use:
Arlevert should be used with caution in patients with increased intraocular pressure, pyloric-duodenal obstruction, enlarged prostate, high blood pressure, increased thyroid function, severe coronary artery disease.
In patients with Parkinson's disease, liver and kidney diseases Arlevert ® should be used with caution because of the risk of accumulation.
Use during pregnancy and lactation
Arlevert safety in pregnant women has not been established, although studies in animals have not shown teratogenic effects. Like other drugs Arlevert use during pregnancy is not recommended.
Dimenhidrinat excreted in small amounts in breast milk and its use by nursing mothers is not recommended.
Effects on ability to drive and use machines:
Arlevert can cause drowsiness, especially in early treatment. In this case, patients should be advised not to drive or operate machinery.
Adverse reactions were rare (<0.1%).
The most common are the reactions of the CNS / eg. drowsiness / and gastrointestinal / eg. dry mouth /. They are usually mild and disappear after a few days, even if treatment is continued.
In rare cases it may be headaches, sweating, visual disturbances, tachycardia (rapid heartbeat), difficulty urinating, and hypersensitivity / eg. skin reactions /.
Very rarely can a reduction in the amount of peripheral blood leukocytes.
Vamozhni side effects due to dimenhidrinat or cinnarizine:
Weight gain, constipation, chest tightness, increased sensitivity to light, increased intraocular pressure, reversible reduction in peripheral blood leukocytes, red flat lichen, lupus-like skin reactions and jaundice vsledstvvie of stagnant bile.
In elderly patients after administration of 150 mg cinnarizine day can be seen shaking legs and increased muscle tone.
Arlevert may potentiate the sedative effects of CNS depressants, including. alcohol, barbiturates, narcotic analgesics, anxiolytics and enhance the effect of anticholinergic drugs such as atropine and tricyclic antidepressants.
Arlevert may increase the effects of ephedrine.
Monoamine oxidase (MAOA and Mao) may potentiate the anticholinergic and sedative effects of antihistamines.
Arlevert may mask ototoxic symptoms / tinnitus, vertigo, deafness or loss of hearing / the use of aminoglycoside antibiotics.
Patients should be advised to avoid the use of alcohol during treatment with Arlevert.
Antihistamines may mask the response to skin tests for allergies.
Dosage and method of administration
Adults and children over 12 years:
1 tablet 3 times daily, to swallow whole with some liquid after meals.
Children under 12 years:
Dosage is as for adults.
At the beginning of treatment and in more severe cases, the dosage may be increased to a maximum of 5 tablets daily.
It is possible to have continuous use of Arlevert.
The duration of treatment is determined by the doctor.
Do not use the medicine after the expiry date.
Store in a dry place inaccessible to children.